Prabhudas Lilladher: Cipla’s Revlimid Settlement With BMS - A Positive Surprise  
Revlimid, a cancer drug is displayed for a photograph. (Photographer Jayme Gershen/Bloomberg)

Prabhudas Lilladher: Cipla’s Revlimid Settlement With BMS - A Positive Surprise  

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Prabhudas Lilladher Report

Cipla Ltd. is now the fourth player to settle Revlimid patent litigation with Bristol Myers Squibb for volume restricted launch post March-CY22E and no volume restriction post January-CY26E.

Volume restriction and launch date are kept confidential, but we believe the company’s settlement agreement could be similar to Dr. Reddys Laboratories Ltd., Natco Pharma Ltd. / Allgergan and Alvogen.

Volume restriction for each player would be capped at 10% of total Revlimid volume for initial years and gradually increase till CY25E, while launch date will be in the order of settlement done.

Click on the attachment to read the full report:

Prabhudas Lilladher Cipla Company Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.